PARP抑制剂用于乳腺癌治疗:综述
本叙述性综述总结了PARP抑制剂在乳腺癌中应用的生物学依据、现有证据、近期进展与潜在未来应用。近期研究显示获益人群扩展至体细胞BRCA1/2变异及胚系PALB2改变患者,在转移和辅助治疗中均有效,但转移性乳腺癌通常无法获得其他瘤种中观察到的长期获益,耐药机制已明确但靶向克服手段 largely 未知,PARP1选择性抑制剂因避免PARP2阻断所致血液学毒性而有前景。
要点
- PARP抑制剂改善了胚系BRCA1/2相关乳腺癌的结局,但几乎所有患者最终出现耐药。
- 获益已扩展至体细胞BRCA1/2变异和胚系PALB2改变患者,转移与辅助治疗均有效。
- 转移性乳腺癌通常无法获得其他瘤种中观察到的PARP抑制剂长期获益。
核心结论
- PARP抑制剂疗效已确立,但许多问题仍存在,未来研究应聚焦于识别预测性生物标志物和克服耐药的策略。
- 将精心设计的转化研究整合到所有临床研究中,对于为正在进行的未来研究见解奠定基础至关重要。
研究设计与样本
- 叙述性综述,总结PARP抑制剂在乳腺癌中应用的生物学依据、现有证据、近期进展和潜在未来应用。
主要发现
- PARP抑制剂是首个能改善遗传性肿瘤患者结局的靶向治疗,已革新胚系BRCA1/2相关乳腺癌的治疗。
- 近期研究显示PARP抑制剂的获益超越胚系BRCA1/2相关转移性乳腺癌患者,扩展至体细胞BRCA1/2变异和胚系PALB2改变患者。
- 这些药物在转移性和辅助治疗中均证明有效。
- 转移性乳腺癌患者通常无法获得其他瘤种中观察到的PARP抑制剂长期获益。
- 耐药机制已被识别,但如何有效靶向这些机制 largely 未知。
临床怎么用
- 原文未据此给出推荐。
局限性
- 转移性乳腺癌患者通常无法获得其他瘤种中观察到的PARP抑制剂长期获益。
- 耐药机制已被识别,但如何有效靶向它们 largely 未知。
- PARP抑制剂疗效已确立,但许多问题仍存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have revolutionized the treatment of patients with germline BRCA1/2-associated breast cancer, representing the first targeted therapy capable of improving outcomes in patients with hereditary tumors. However, resistance to PARP inhibitors occurs in almost all patients. OBSERVATIONS: This narrative review summarizes the biological rationale behind the use of PARP inhibitors in breast cancer, as well as the available evidence, recent progress, and potential future applications of these agents. Recent studies have shown that the benefit of PARP inhibitors extends beyond patients with germline BRCA1/2-associated metastatic breast cancer to patients with somatic BRCA1/2 variants and to those with germline PALB2 alterations. Moreover, these agents proved to be effective both in the metastatic and adjuvant settings. However, patients with metastatic breast cancer usually do not achieve the long-term benefit from PARP inhibitors observed in other tumor types. Mechanisms of resistance have been identified, but how to effectively target them is largely unknown. Ongoing research is investigating both novel therapeutics and new combination strategies to overcome resistance. PARP1-selective inhibitors, by sparing the hematological toxic effects induced by the PARP2 blockade, are promising agents to be combined with chemotherapy, antibody-drug conjugates, and other targeted therapies. CONCLUSIONS AND RELEVANCE: Although the efficacy of PARP inhibitors is well established, many questions persist. Future research should focus on identifying predictive biomarkers and therapeutic strategies to overcome resistance. Integrating well-designed translational efforts into all clinical studies is thereby crucial to laying the groundwork for future insights from ongoing research.
引用
- Morganti S, Marra A, De Angelis C, et al. PARP Inhibitors for Breast Cancer Treatment: A Review. JAMA Oncol. 2024. PMID: 38512229. doi:10.1001/jamaoncol.2023.7322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。